三甘油糖指数与高尿血的关联:剂量反应元分析
Juan Wang1, Qiang He2, Wenhui Sun1
1Department of Nutrition and Food Hygiene, School of Public Health, Jilin University, Changchun 130021, China.
Nutrients
|May 14, 2025
概括
甘油三糖 (TyG) 指数与高尿血症的更高风险有关. 增加的TyG指数水平与患这种疾病的机会增加有显著的相关性.
科学领域:
- 代谢综合征是代谢综合征的一种.
- 心血管健康 心血管健康
背景情况:
- 三甘油糖 (TyG) 指数是胰岛素耐药性的标志物.
- 之前的研究表明,TyG指数与各种疾病之间存在关联.
- 泰格指数和高尿路血症之间的关系仍在争论中.
研究的目的:
- 进行一项元分析,调查TyG指数与高尿血症之间的关联.
- 综合现有证据,以澄清TyG指数和高尿血症之间的有争议的联系.
主要方法:
- 对相关研究进行了系统的元分析.
- 数据从电子数据库中提取到2025年3月.
- 使用随机效应模型计算效应大小和95%置信区间 (CI).
主要成果:
- 分析包括26项试验,共有637,954名参与者.
- 在TyG指数和高尿血症之间发现了显著的关联 (OR = 2.67;95% CI: 2.34, 3.04).
- 剂量反应分析表明,每增加1mg/dL的TyG指数,就会增加2.07倍的高尿路血症风险 (OR=2.07;95%CI:1.89,2.25).
结论:
- 泰格指数与高尿血症有显著的关联.
- 由于元分析的局限性,建议进行进一步的前性队列研究以验证这些发现.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
Oral Hypoglycemic Agents: Sulfonylureas
167
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
167
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Dipeptidyl Peptidase 4 Inhibitors
142
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
142
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
130
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
130
Oral Hypoglycemic Agents: Glinides
114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114


